Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) shares were down 1.9% during trading on Wednesday . The stock traded as low as $17.19 and last traded at $17.56. Approximately 972,931 shares traded hands during trading, an increase of 188% from the average daily volume of 337,931 shares. The stock had previously closed at $17.90.
Silverback Therapeutics Stock Down 2.3%
The stock has a 50-day moving average of $15.50 and a 200 day moving average of $13.62. The stock has a market cap of $646.16 million, a PE ratio of -7.40 and a beta of 0.60.
Silverback Therapeutics Company Profile
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Articles
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
